This study is in progress, not accepting new patients

Biospecimen Analysis in Determining Effects of Chemotherapy on Fertility in Osteosarcoma Survivors

a study on Bone Cancer Osteosarcoma

Summary

Eligibility
for males ages 18-50 (full criteria)
Location
at Oakland, California and other locations
Dates
study started
completion around

Description

Summary

This research trial studies saliva, semen, and blood samples to determine effects of chemotherapy on fertility in osteosarcoma survivors. Study biospecimen samples from osteosarcoma survivors in the laboratory may help doctors learn whether chemotherapy causes fertility problems and to learn more about the long term effects.

Official Title

Effects of Modern Chemotherapy Regimens on Spermatogenesis and Steroidogenesis in Adolescent and Young Adult (AYA) Survivors of Osteosarcoma

Details

PRIMARY OBJECTIVES:

  1. Determine whether infertility and/or biomarkers of spermatogenesis and steroidogenesis differ in male osteosarcoma survivors treated with cisplatin with or without ifosfamide compared to male controls without a history of cancer.

II. Evaluate whether cisplatin with or without ifosfamide for the treatment of osteosarcoma alters sperm deoxyribonucleic acid (DNA) methylation.

EXPLORATORY OBJECTIVES:

  1. Evaluate the role of genetic susceptibility in the development of impairments in spermatogenesis or steroidogenesis with contemporary regimens for the treatment of osteosarcoma.

OUTLINE:

Participants complete a health questionnaire over 30-45 minutes. Patients also provide saliva and semen samples and undergo collection of blood.

Keywords

Osteosarcoma, Biospecimen Collection, Laboratory Biomarker Analysis

Eligibility

For males ages 18-50

Inclusion Criteria:

  • Received upfront therapies for osteosarcoma, which included cisplatin, (with or without other agents)
  • Patient must have completed cancer treatment >= 2 years prior to study enrollment
  • Osteosarcoma survivors without a systemically treated relapse or subsequent malignancy
    • Note: History of relapse or second malignancy is permitted if treated with local therapy only (e.g. surgery, radiation)
  • Able to speak, read and write in English, French or Spanish
  • All patients and/or their parents or legal guardians must sign a written informed consent
  • All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met

Locations

  • UCSF Benioff Children's Hospital Oakland
    Oakland California 94609 United States
  • Kaiser Permanente-Oakland
    Oakland California 94611 United States
  • Lucile Packard Children's Hospital Stanford University
    Palo Alto California 94304 United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Children's Oncology Group
ID
NCT03206450
Study Type
Observational
Participants
About 224 people participating
Last Updated